Modality
mRNA
MOA
STINGag
Target
DLL3
Pathway
RAS/MAPK
DravetASBCC
Development Pipeline
Preclinical
~May 2018
→ ~Aug 2019
Phase 1
Nov 2019
→ Jan 2027
Phase 1Current
NCT03221320
2,966 pts·BCC
2021-07→2027-01·Recruiting
NCT05225571
1,992 pts·Dravet
2019-11→TBD·Active
4,958 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-01-2210mo awayPh2 Data· BCC
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
P1/2
Active
P1/2
Recruit…
Catalysts
Ph2 Data
2027-01-22 · 10mo away
BCC
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03221320 | Phase 1/2 | BCC | Recruiting | 2966 | LiverFat |
| NCT05225571 | Phase 1/2 | Dravet | Active | 1992 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| RHH-5389 | Roche | Preclinical | RET | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| AMG-7379 | Amgen | Preclinical | DLL3 |